The German molecular diagnostics firm plans to list on Euronext in Amsterdam and Euronext in Brussels.
Market worries earlier this week have left some in biotech shaken, FierceBiotech says.
The company filed to go public in March with plans to offer up to $60 million of its stock.
The firm will withdraw its planned IPO after being told that it would have to take a 30 to 40 percent discount to its valuation, its CEO said.
The $180 million offering is well above the firm's initial target for proceeds of $100 million.
The firm said in an SEC document that it plans to offer 6.25 million shares and expects net proceeds of up to $103.3 million.
Revenues for the quarter dropped about 55 percent compared to revenues for the same quarter in 2014.
In addition to offering NIPTs, Natera is eyeing the cancer diagnostics space.
The IPO could bring in $51.4 million in net proceeds for the molecular diagnostics firm.
The microbial genetics analysis firm went public today offering 2.85 million units for $17.1 million in gross proceeds.
A new analysis finds that nearly half the late-stage clinical trials sponsored by a US National Cancer Institute program influence patient care.
Technology Review reports that sickle cell patients are optimistic about gene editing to treat their disease, but are worried about how available it will be.
The owner of the GEDmatch website tells CBS12 he is considering charging law enforcement a fee to use the site.
In Nature this week: babies born by caesarean section are more likely to have altered gut microbiota profiles, and more.